Pharmaceutical

Filter

Current filters:

None

Popular Filters

51 to 75 of 7009 results

China tops pharmaceutical material suppliers for Vietnam

China tops pharmaceutical material suppliers for Vietnam

08-09-2014

China is the largest supplier of pharmaceutical materials for Vietnam in the first seven months of 2014,…

AsiaAustriaBusiness FinanceChinaIndiaMarkets & MarketingPharmaceuticalVietnamXinhua

Meiji and Takeda to co-promote Rozerem for insomnia

Meiji and Takeda to co-promote Rozerem for insomnia

08-09-2014

Fellow Japanese drugmakers Meiji Seika Pharma and Takeda Pharmaceutical have finalized a co-promotion…

JapanLicensingMeiji Seika PharmaNeurologicalPharmaceuticalRozeremTakeda Pharmaceutical

GSK reports positive Phase III results of its mepolizumab in asthma

GSK reports positive Phase III results of its mepolizumab in asthma

08-09-2014

UK pharma major GlaxoSmithKline has reported positive data from its Phase III asthma studies of mepolizumab,…

GlaxoSmithKlineGSKImmunosuppressantsmepolizumabMepolizumabPharmaceuticalResearchRespiratory and PulmonaryUK

Roche’s RoActemra gains EU approval for use in early RA

Roche’s RoActemra gains EU approval for use in early RA

08-09-2014

The European Commission has approved Swiss pharma major Roche’s RoActemra (tocilizumab) for use in…

ActemraAnti-Arthritics/RheumaticsEuropeInterleukin 6PharmaceuticalRegulationRoActemraRoche

Astellas' isavuconazole NDA accepted by US FDA

Astellas' isavuconazole NDA accepted by US FDA

08-09-2014

The US Food and Drug Administration has accepted a New Drug Application filing by Japanese drug major…

Astellas PharmaFungal diseasesInvasive aspergillosisInvasive mucormycosisisavuconazoleOncologyPharmaceuticalRegulationUSA

New report debunks some common perceptions of R&D productivity

New report debunks some common perceptions of R&D productivity

08-09-2014

The 2014 edition of the Thomson Reuters CMR Pharmaceutical R&D Factbook, published today, contains some…

GlobalMarkets & MarketingPharmaceuticalRegulationResearch

Chugai launches ALK inhibitor Alecensa in Japan

Chugai launches ALK inhibitor Alecensa in Japan

07-09-2014

Japanese drugmaker Chugai Pharmaceutical said on Friday that it has launched the ALK inhibitor Alecensa…

AlecensaalectinibChugai PharmaceuticalJapanMarkets & MarketingOncologyPharmaceuticalRoche

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

07-09-2014

US specialty drugmaker Depomed says that Judge Kentaji Brown Jackson of the federal district court for…

DepomedGraliseLegalNeurologicalPharmaceuticalRare diseasesUSA

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

05-09-2014

US drugmaker Mallinckrodt reported that a Phase III efficacy trial of investigational MNK-155 met the…

AcuformDepomedMallinckrodtMNK-155NeurologicalPharmaceuticalResearch

FDA accepts Actavis’ NDA for ceftazidime-avibactam

FDA accepts Actavis’ NDA for ceftazidime-avibactam

05-09-2014

Ireland-headquartered generic drugs major Actavis today confirmed that the US Food and Drug Administration…

ActavisAntibiotics and Infectious diseasesceftazidime-avibactamPharmaceuticalRegulationResearchUSA

Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

05-09-2014

Swiss/Greek pharmaceutical and clinical research group Sellas Life Sciences Group has signed an exclusive…

GlobalLicensingOncologyPharmaceuticalSellas Life SciencesVaccines

Breast cancer has Pharma’s largest and most innovative drug pipeline; report

Breast cancer has Pharma’s largest and most innovative drug pipeline; report

05-09-2014

The breast cancer therapeutics pipeline boasts a high degree of innovation in first-in-class molecules,…

OncologyPharmaceuticalResearch

Ablynx launches American Depository Receipt program to expand US investor base

Ablynx launches American Depository Receipt program to expand US investor base

05-09-2014

Belgian drug developer Ablynx has launched a Sponsored Level I American Depository Receipt (ADR) program…

AblynxBusiness FinanceFinancialInvestmentPharmaceuticalStock marketUSA

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

05-09-2014

The US Food and Drug Administration has granted accelerated approval for pharma giant Merck & Co’s…

KeytrudaMerck & CoOncologypembrolizumabPharmaceuticalRegulationUSA

IQWiG finds no added benefit for Astellas’ Betmiga

IQWiG finds no added benefit for Astellas’ Betmiga

04-09-2014

Japanese drug major Astellas Pharma's Betmiga (mirabegron), which has been approved in Germany since…

Astellas PharmaBetmigaGenito-urinaryGermanyPharmaceutical

Redx Pharma and AstraZeneca collaborate on oncology research

04-09-2014

UK-based drug discovery firm Redx Pharma says it has entered into a research collaboration with Anglo-Swedish…

AstraZenecaOncologyPharmaceuticalRedx PharmaResearch

51 to 75 of 7009 results

Back to top